Your browser doesn't support javascript.
loading
Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.
Seedat, Faheem; Patel, Moosa; Phillip, Vinitha; Mohamed, Farzahna; Marais, A David; Blackhurst, Dee M; Solomon, Gabriele; Currin, Sean; Raal, Frederick J.
Afiliação
  • Seedat F; Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: faheem@global.co.za.
  • Patel M; Division of Clinical Hematology, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Phillip V; Division of Clinical Hematology, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Mohamed F; Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Marais AD; Division of Chemical Pathology, University of Cape Town Health Science Faculty, Cape Town, South Africa.
  • Blackhurst DM; Division of Chemical Pathology, University of Cape Town Health Science Faculty, Cape Town, South Africa.
  • Solomon G; Division of Chemical Pathology, University of Cape Town Health Science Faculty, Cape Town, South Africa.
  • Currin S; Department of Chemical Pathology, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
  • Raal FJ; Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Clin Chim Acta ; 520: 71-75, 2021 Sep.
Article em En | MEDLINE | ID: mdl-34052205
ABSTRACT
Dysbetalipoproteinemia (DBL) is an uncommon condition characterized by a mixed hyperlipidemia due to accumulation of remnant lipoproteins and is highly atherogenic. Typically, DBL is an autosomal recessive condition requiring an additional metabolic stress with reduced apolipoprotein E (apoE) function. However, DBL is also described in patients with multiple myeloma without the characteristic apoE2/E2 mutation seen in familial DBL. Although the underlying pathogenesis in these cases is not fully characterized, it is thought to occur due to interference with apoE function by antibodies produced from clonal plasma cells. Such cases are referred to as hyperlipidemic myeloma (HLM) and have rarely been described in the literature. To our knowledge there is no prior description of HLM in HIV positive patients in Africa. We describe a case of HLM in an African woman with underlying HIV infection who presented with phenotypic and biochemical features of DBL that responded poorly to lipid lowering therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Hiperlipoproteinemia Tipo III / Mieloma Múltiplo Limite: Female / Humans País/Região como assunto: Africa Idioma: En Revista: Clin Chim Acta Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Hiperlipoproteinemia Tipo III / Mieloma Múltiplo Limite: Female / Humans País/Região como assunto: Africa Idioma: En Revista: Clin Chim Acta Ano de publicação: 2021 Tipo de documento: Article